Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Biome Tech LSE:BIOM London Ordinary Share GB00B9Z1M820 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00p -1.83% 535.00p 520.00p 550.00p 545.00p 535.00p 545.00p 1,062 12:20:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Industrial Engineering 6.2 -0.4 -10.0 - 12.64

Biome Technologies PLC Interim Results

03/09/2018 7:00am

UK Regulatory (RNS & others)


Biome Technologies (LSE:BIOM)
Historical Stock Chart

6 Months : From Jun 2018 to Dec 2018

Click Here for more Biome Technologies Charts.

TIDMBIOM

RNS Number : 4859Z

Biome Technologies PLC

03 September 2018

3 September 2018

Biome Technologies plc

("Biome", "the Company" or "the Group")

Interim Results

Biome Technologies plc announces its Interim Results for the six months ended 30 June 2018.

Highlights

-- Group revenues in H1 2018 increased by 47% to GBP4.4m compared with the comparable period last year (H1 2017: GBP3.0m)

-- Biome generated an operating profit of GBP0.2m compared to an operating loss of GBP0.2m in the first half of 2017

   --      Group cash position at 30 June 2018 of GBP2.3m (31 December 2017: GBP2.3m) 

Paul Mines, Chief Executive Officer said:

"The Group had an outstanding first half to 2018 delivering an operating profit in the period. Opportunities within the Bioplastics division are increasing with substantial revenue potential in the medium term whilst the Stanelco RF division has delivered an exceptional start to the year. It is against this backdrop that Board remains confident in the Group's outlook for 2018."

 
 
 
 
   For further information please contact: Biome 
   Technologies plc 
 
   Paul Mines, Chief Executive Officer 
 Declan Brown, Group Finance Director 
 www.biometechnologiesplc.com   Tel: +44 (0) 2380 867 
                                 100 
 
   Allenby Capital 
 David Hart/Alex Brearley (Nominated Adviser) 
  Kelly Gardiner (Broker) 
 www.allenbycapital.com         Tel: +44 (0) 20 3328 
                                 5656 
 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

In 2018, the Board has adopted the following three high level KPIs for the next three years to continue its ambitious momentum:

-- Compound revenue growth of 25% per annum across the Group and 40% compound revenue growth in the Bioplastics division

-- Diversify the Group's turnover by product and market to ensure that no one product or end customer contributes more than 15% of revenues by 2020

-- Increase investment in the Group's next generation of products by spending significantly more per annum on average than the GBP0.3m per annum average spend over the previous strategic objective cycle

www.biometechnologiesplc.com

www.biomebioplastics.com

www.stanelcorftechnologies.com

Chairman's Statement

The Group has reached an important milestone in the first half of 2018 by reporting an operating profit of GBP0.2m, substantially ahead of the operating loss of GBP0.2m in the prior year.

Group revenues were up 47% to GBP4.4m compared to GBP3.0m in the first half of 2017 due to an exceptional increase in revenues in the RF Technologies division. Gross profit of GBP2.3m was ahead of the first half of 2017 (GBP1.5m). Margins, at 53%, were ahead of the prior year due mainly to a favourable product mix. Overheads increased by GBP0.4m over 2017 principally reflecting increased staffing levels to support the increase in turnover as well as increased research and development spend associated with the next generation of products within the Bioplastics division.

The Group recorded a profit before interest, depreciation, amortisation and share option charges for the six months to 30 June 2018 of GBP0.5m compared to a profit of GBP0.1m in the first half of 2017. The profit after taxation was GBP0.2m (H1 2017: loss GBP0.2m) equating to earnings per share of 9 pence on both a basic and diluted basis (H1 2017 loss per share 9 pence).

The Group's cash position as at 30 June 2018 was GBP2.3m (31 December 2017: GBP2.3m).

Biome Bioplastics Division

Revenues in the Bioplastics division for the first half of 2018 were GBP0.9m (H1 2017: GBP1.2m) with the turnover in the second quarter returning to a normal pattern within the existing single serve coffee pod packaging business. Sales of the non-woven mesh filtration product continued to grow as expected and Biome's work to qualify a second manufacturing site in the USA in anticipation of additional demand is nearing completion. It is anticipated that sales of the reformulated rigid ring material for coffee pods will commence in Q4 2018 and testing continues in this regard.

The operating loss for the period of GBP0.3m (2017: operating loss of GBP0.1m) reflects the impact of the lower revenues as well as the acceleration of research and development costs associated with next generation products and the increase in staffing resource to support the anticipated increase in demand for bioplastics products. The division's development compounding capabilities were expanded to a second location in Southampton during the period.

Biome continues its strategy of developing products where there is specific customer demand for bio-based or biodegradable solutions. It was noted in the July 2018 trading update that two projects in particular are advancing encouragingly through the development phase and, if successful, could lead to substantial revenues in 2019 and 2020. These projects are both with new customers. One of them has now completed its technical development phase in the USA and commercial production is expected in 2019. The second project, being developed in continental Europe, has passed an important milestone in recent weeks and work continues to support an aggressive launch timetable with the customer with commercial revenues being anticipated in 2019. Additionally, in recent weeks an initial six-month feasibility study, supported by an international consumer goods company, has been completed and discussions are underway regarding a product launch in 2020.

The division has continued with its mid-term strategy to develop a new range of lignocellulose-derived bioplastics that have increased performance characteristics and can be made at a comparable cost to traditional petro-chemicals. This work continues to be supported by various government grants and during the first half of 2018 the Company accelerated expenditure in this area. The Company has now filed a number of patent applications to protect the emerging technology (details of these can be found under the Biotechnology section of the Company's Biome Bioplastics website). Further updates on the progress of these projects will be made as they evolve.

Positive interest remains in the UK, with the Government looking to progress innovative material solutions to the problem of single use plastics in the medium term. This may provide an opportunity to accelerate our work in industrial biotechnology solutions and Biome is engaged with a number of parties in this area.

Stanelco RF Technologies Division

Revenues in the RF Technologies division were GBP3.5m (H1 2017: GBP1.7m) reflecting exceptional demand in the period for fibre optic furnaces. As a result of this substantial increase in revenues, operating profit recorded in the first half increased to GBP1.3m (H1 2017: GBP0.6m).

Strong demand for fibre optic furnaces continues into the second half of this year. The design and manufacturing teams have responded very well to the rapid and significant upturn in activity. The manufacturing footprint was expanded during the period providing increased production capacity.

Outlook

As can be seen from the above updates, our divisions are maximising their opportunities within quite different business environments and the Board remains confident in the Group's outlook for 2018.

Bioplastics is developing a position in a new market with substantial incremental growth prospects. The recent widening of its customer base and products under development, as its marketplace increases in size, is giving more evidence that we will achieve our strategic goals on the three-year horizon set out in our last annual report.

RF Technologies operates in a highly technical, export-led and established market for its products. It is making the most of the demand in this exceptional period of expansion, albeit the likelihood of continuing on the present trajectory is not anticipated in our current strategic assessment of RF Technologies.

The above emphasises to us the importance of both a three-year view and the benefit of balancing the current outperformance of RF Technologies with the substantial opportunities available to Biome in the mid-term.

We will be updating shareholders more fully at the end of the year regarding our KPI performance.

John Standen

Chairman

 
 CONSOLIDATED STATEMENT 
 OF COMPREHENSIVE INCOME 
 For the period ended 30 June 2018 
                                                          Total       Total 
                                                            for         for 
                                                       6 Months    6 Months    Total Year 
                                                          Ended       Ended         Ended 
                                                        30 June     30 June   31 December 
                                                           2018        2017          2017 
                                                      Unaudited   Unaudited       Audited 
                                               Note     GBP'000     GBP'000       GBP'000 
--------------------------------------------  -----  ----------  ----------  ------------ 
 
                                               5a - 
 REVENUE                                        5c        4,391       2,979         6,233 
 Cost of sales                                          (2,068)     (1,497)       (3,131) 
 
 GROSS PROFIT                                             2,323       1,482         3,102 
 
 Administrative expenses                                (2,117)     (1,688)       (3,513) 
 
                                               5a - 
 PROFIT/(LOSS) FROM OPERATIONS                  5c          206       (206)         (411) 
 
 Profit/(Loss) from operations before 
  share options charges                                     311       (180)         (365) 
 Share options charges                                    (105)        (26)          (46) 
 
 Investment revenue                                           2           1             1 
 Foreign exchange gain/(loss)                                 8        (14)          (32) 
 
 PROFIT/(LOSS) BEFORE TAXATION                              216       (219)         (442) 
 Taxation                                       6             -           -           210 
 
 TOTAL COMPREHENSIVE INCOME FOR THE 
  PERIOD ATTRIBUTABLE TO THE EQUITY HOLDERS 
  OF THE PARENT                                             216       (219)         (232) 
                                                     ==========  ==========  ============ 
 
 Basic earnings/(loss) per share - pence        7             9         (9)          (10) 
 Diluted earnings/(loss) per share - 
  pence                                         7             9         (9)          (10) 
 
 
 CONSOLIDATED STATEMENT 
 OF FINANCIAL POSITION 
 As at 30 June 2018 
                                                        At          At            At 
                                                   30 June     30 June   31 December 
                                                      2018        2017          2017 
                                                 Unaudited   Unaudited       Audited 
                                          Note     GBP'000     GBP'000       GBP'000 
---------------------------------------  -----  ----------  ----------  ------------ 
 
 NON-CURRENT ASSETS 
 Other intangible assets                   8           891       1,035           915 
 Property, plant and equipment             9           161         136           122 
                                                ----------  ----------  ------------ 
                                                     1,052       1,171         1,037 
                                                ----------  ----------  ------------ 
 
 CURRENT ASSETS 
 Inventories                               10          861         630           797 
 Trade and other receivables               11        1,555       1,515         1,335 
 Cash and cash equivalents                           2,307       1,885         2,293 
                                                ----------  ----------  ------------ 
                                                     4,723       4,030         4,425 
                                                ----------  ----------  ------------ 
 
 TOTAL ASSETS                                        5,775       5,201         5,462 
                                                ==========  ==========  ============ 
 
 CURRENT LIABILITIES 
 Trade and other payables                  12        2,063       1,871         2,125 
                                                     2,063       1,871         2,125 
                                                ----------  ----------  ------------ 
 
 TOTAL LIABILITIES                                   2,063       1,871         2,125 
                                                ==========  ==========  ============ 
 
 NET ASSETS                                          3,712       3,330         3,337 
                                                ==========  ==========  ============ 
 
 EQUITY 
 Share capital                                         118         117           117 
 Share premium account                                 793         740           740 
 Capital redemption reserve                              4           4             4 
 Share options reserve                                 214         480           219 
 Translation reserve                                  (85)        (85)          (85) 
 Retained profits/(losses)                           2,668       2,074         2,342 
 
 EQUITY ATTRIBUTABLE TO EQUITY HOLDERS 
  OF THE PARENT AND TOTAL EQUITY                     3,712       3,330         3,337 
                                                ==========  ==========  ============ 
 

The interim statements were approved by the Board on 31 August 2018.

Signed on behalf of the Board of Directors

Paul R Mines (Chief Executive)

Declan L Brown (Group Finance Director)

31 August 2018

 
 CONSOLIDATED STATEMENT 
  OF CHANGES IN EQUITY 
 As at 30 June 2018 
                                           Share       Capital      Share 
                                Share    premium    redemption    options   Translation    Retained     TOTAL 
                              capital    account       reserve    reserve       reserve    earnings    EQUITY 
                              GBP'000    GBP'000       GBP'000    GBP'000       GBP'000     GBP'000   GBP'000 
 Unaudited 
 Balance at 1 January 
  2018                            117        740             4        219          (85)       2,342     3,337 
                            =========  =========  ============  =========  ============  ==========  ======== 
 
 Issue of share capital             1         53             -          -             -           -        54 
 Share options issued 
  in share based payments           -          -             -        105             -           -       105 
 Cancellation of 
  time expired share 
  options                           -          -             -      (110)             -         110         - 
                            ---------  ---------  ------------  ---------  ------------  ----------  -------- 
 Transactions with 
  owners                            1         53             -        (5)             -         110       159 
                            ---------  ---------  ------------  ---------  ------------  ----------  -------- 
 
 Profit for the period              -          -             -          -             -         216       216 
 Total comprehensive 
  income for the period             -          -             -          -             -         216       216 
                            ---------  ---------  ------------  ---------  ------------  ----------  -------- 
 
 
 Balance 30 June 
  2018                            118        793             4        214          (85)       2,668     3,712 
                            =========  =========  ============  =========  ============  ==========  ======== 
 
 
 
 Unaudited 
 Balance at 1 January 
  2017                            117        740             4        454          (85)       2,293     3,523 
                            =========  =========  ============  =========  ============  ==========  ======== 
 
 Share options issued 
  in share based payments           -          -             -         26             -           -        26 
 Cancellation of 
  time expired share 
  options                           -          -             -          -             -           -         - 
 
 Transactions with 
  owners                            -          -             -         26             -           -        26 
                            ---------  ---------  ------------  ---------  ------------  ----------  -------- 
 
 Loss for the period                -          -             -          -             -       (219)     (219) 
 
 
 Total comprehensive 
  income for the period             -          -             -          -             -       (219)     (219) 
                            ---------  ---------  ------------  ---------  ------------  ----------  -------- 
 
 Balance 30 June 
  2017                            117        740             4        480          (85)       2,074     3,330 
                            =========  =========  ============  =========  ============  ==========  ======== 
 
 
 
 
 
                                           Share       Capital      Share 
                                Share    premium    redemption    options   Translation    Retained     TOTAL 
                              capital    account       reserve    reserve      reserves    earnings    EQUITY 
                              GBP'000    GBP'000       GBP'000    GBP'000       GBP'000     GBP'000   GBP'000 
 Audited 
 Balance at 1 January 
  2017                            117        740             4        454          (85)       2,293     3,523 
                            =========  =========  ============  =========  ============  ==========  ======== 
 
 Share options issued 
  in share based payments           -          -             -         46             -           -        46 
 Cancellation of 
  time expired share 
  options                           -          -             -      (281)             -         281         - 
 
 Transactions with 
  owners                            -          -             -      (235)             -         281        46 
                            ---------  ---------  ------------  ---------  ------------  ----------  -------- 
 
 Loss for the year                  -          -             -          -             -       (232)     (232) 
 
 Total comprehensive 
  income for the year               -          -             -          -             -       (232)     (232) 
                            ---------  ---------  ------------  ---------  ------------  ----------  -------- 
 
 Balance 31 December 
  2017                            117        740             4        219          (85)       2,342     3,337 
                            =========  =========  ============  =========  ============  ==========  ======== 
 
 
 CONSOLIDATED STATEMENT 
 OF CASH FLOWS 
 For the period ended 30 June 2018 
 
 
                                               6 Months    6 Months          Year 
                                                  Ended       Ended         ended 
                                                30 June     30 June   31 December 
                                                   2018        2017          2017 
                                              Unaudited   Unaudited       Audited 
                                                GBP'000     GBP'000       GBP'000 
-------------------------------------------  ----------  ----------  ------------ 
 
 Profit/(loss) from operations                      206       (206)         (411) 
 Adjustment for: 
 Amortisation and impairment of intangible 
  assets                                            145         203           355 
 Depreciation of property, plant and 
  equipment                                          29          31            64 
 Share based payments                               105          26            46 
 Foreign exchange                                     8        (11)          (26) 
                                             ----------  ----------  ------------ 
 Operating cash flows before movement 
  of working capital                                493          43            28 
 (Increase)/Decrease in inventories                (63)       (249)         (417) 
 (Increase)/decrease in receivables               (220)       (174)             5 
 Increase/(decrease) in payables                   (62)         805         1,059 
                                             ----------  ----------  ------------ 
 Cash utilised in operations                        148         425           675 
 Corporation tax (paid)/received                      -           -           210 
                                             ----------  ----------  ------------ 
 Net cash inflow from operating activities          148         425           885 
                                             ----------  ----------  ------------ 
 
 Cash flows from investing activities 
 Interest received                                    2           1             1 
 Investment in intangible assets                  (122)        (73)         (106) 
 Purchase of property, plant and equipment         (68)         (3)          (22) 
                                             ----------  ----------  ------------ 
 Net cash used in investing activities            (188)        (75)         (127) 
                                             ----------  ----------  ------------ 
 
 Financing activities 
 Proceeds from issue of ordinary shares              54           -             - 
                                             ----------  ----------  ------------ 
 Net cash inflow from financing activities           54           -             - 
                                             ----------  ----------  ------------ 
 
 Net increase in cash and cash equivalents           14         350           758 
 
 Cash and cash equivalents at beginning 
  of period                                       2,293       1,535         1,535 
                                             ----------  ----------  ------------ 
 Cash and cash equivalents at end 
  of period                                       2,307       1,885         2,293 
                                             ==========  ==========  ============ 
 

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

For the period ended 30 June 2018

1. CORPORATE INFORMATION

The financial information for the year ended 31 December 2017 set out in this interim report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the year ended 31 December 2017 have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain statements under Section 498 of the Companies Act 2006. The interim results are unaudited. Biome Technologies plc is a public limited company incorporated and domiciled in England & Wales. The company's shares are publicly traded on the AIM market of the London Stock Exchange.

2. BASIS OF PREPARATION

These interim consolidated financial statements (the interim financial statements) are for the six months ended 30 June 2018. They have been prepared in accordance with IFRSs as adopted by the European Union and IAS 34 Interim Financial Reporting. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 31 December 2017.

These interim financial statements have been prepared under the historical cost convention.

These interim financial statements have been prepared in accordance with the accounting policies adopted in the last annual financial statements for the year to 31 December 2017 except for the adoption of IFRS 15 as described below.

On 1 January 2018 the Group adopted IFRS 15 'Revenue from Contracts with Customer' which supersedes IAS 18 'Revenue'. The Group has adopted the 'Modified retrospective application' which means there is no restatement of the comparative period but there is an opening adjustment to retained earnings as at 1 January 2018 to account for any earnings taken in 2017 that need to be reclassified to 2018. Following a review of all revenue streams it has been determined that no opening adjustments with respect to the adoption of IFRS 15 are required.

The accounting policies have been applied consistently throughout the Group for the purposes of preparation of the interim financial statements.

3. BASIS OF CONSOLIDATION

The Group interim financial statements consolidate the results of the Company and all of its subsidiary undertakings drawn up to 30 June 2018. At 30 June 2018 the subsidiary undertakings were Biome Bioplastics Limited, Stanelco RF Technologies Limited, Aquasol Limited and InGel Technologies Limited.

4. GOING CONCERN

The directors have reviewed forecasts and budgets for the coming 12 months, which have been drawn up with appropriate regard for the current macroeconomic environment and the particular circumstances in which the Group operates. As a result of this process, the directors are satisfied that the group have sufficient resources to continue in operational existence for at least one year from the date of approval of the interim report.

5a. SEGMENTAL INFORMATION FOR 6 MONTHSED 30 JUNE 2018

 
                                                             RF    Central 
                                    Bioplastics    Technologies      Costs      Total 
                                       6 Months        6 Months   6 Months   6 Months 
                                          Ended           ended      ended      Ended 
                                        30 June         30 June    30 June    30 June 
                                           2018            2018       2018       2018 
                                        GBP'000         GBP'000    GBP'000    GBP'000 
 Unaudited 
 Revenue from external customers            932           3,459          -      4,391 
 
 (LOSS)/PROFIT FROM OPERATIONS            (345)           1,279      (728)        206 
 Investment revenue                                                                 2 
 Foreign exchange gain                                                              8 
 
 PROFIT ATTRIBUTABLE TO EQUITY 
  SHAREHOLDERS                                                                    216 
                                                                            ========= 
 
 TOTAL ASSETS                             1,940           1,931      1,904      5,775 
=================================  ============  ==============  =========  ========= 
 

5b. SEGMENTAL INFORMATION FOR 6 MONTHSED 30 JUNE 2017

 
                                                             RF    Central 
                                    Bioplastics    Technologies      Costs      Total 
                                       6 Months        6 Months   6 Months   6 Months 
                                          ended           Ended      ended      Ended 
                                        30 June         30 June    30 June    30 June 
                                           2017            2017       2017       2017 
                                        GBP'000         GBP'000    GBP'000    GBP'000 
 Unaudited 
 Revenue from external customers          1,241           1,738          -      2,979 
 
 (LOSS)/PROFIT FROM OPERATIONS            (139)             558      (625)      (206) 
 Investment revenue                                                                 1 
 Foreign exchange loss                                                           (14) 
 
 LOSS ATTRIBUTABLE TO EQUITY 
  SHAREHOLDERS                                                                  (219) 
                                                                            ========= 
 
 TOTAL ASSETS                             1,550           1,754      1,897      5,201 
=================================  ============  ==============  =========  ========= 
 

5c. SEGMENTAL INFORMATION FOR YEAR ENDED 31 DECEMBER 2017

 
                                                             RF       Central 
                                    Bioplastics    Technologies         Costs       Total 
                                           Year            Year          Year        Year 
                                          ended           ended         ended       ended 
                                             31              31                        31 
                                       December        December   31 December    December 
                                           2017            2017          2017        2017 
                                        GBP'000         GBP'000       GBP'000     GBP'000 
 Audited 
 Revenue from external customers          2,279           3,954             -       6,233 
 
 (LOSS)/PROFIT FROM OPERATIONS            (421)           1,338       (1,328)       (411) 
 
 Investment revenue                                                                     1 
 Foreign exchange loss                                                               (32) 
 
 LOSS BEFORE TAXATION FROM 
  OPERATIONS                                                                        (442) 
 
 Taxation                                                                             210 
 
 LOSS ATTRIBUTABLE TO EQUITY 
  SHAREHOLDERS                                                                      (232) 
                                                                               ========== 
 
 TOTAL ASSETS                             1,795           1,380         2,287       5,462 
=================================  ============  ==============  ============  ========== 
 

6. TAXATION

The Group's policy is to recognise tax credits resulting from tax R&D claims on a cash received basis. The claim in respect of the year ended 31 December 2017 has not yet been settled and there is therefore no tax credit recognised in the period under review.

7. EARNINGS PER SHARE

The calculation of basic earnings per share is based on the profit attributable to the equity holders of the parent for the six months of GBP216,000 (2017: loss of GBP219,000) and a weighted average of 2,352,465 (2017: 2,347,536) ordinary shares in issue.

Diluted earnings per share for the six months ended 30 June 2018 were based on a weighted average of 2,484,334 shares which accounts for all share options which are in the money, regardless of whether they have yet vested. For 2017 the diluted earnings per share equalled the basic earnings per share as all outstanding share options were out of the money for the purposes of the diluted earnings per share calculation.

8. OTHER INTANGIBLE ASSETS

Other intangible assets decreased in the period as a result of the amortisation charge of GBP145,000 exceeding the capitalisation of product development costs for the period of GBP122,000.

9. PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment increased in the reporting period as a result of the purchase of property, plant and equipment of GBP68,000 being more than the depreciation charge for the period of GBP29,000.

10. INVENTORIES

The increase in inventories during the reporting period reflects the increase in equipment orders under construction within the Stanelco RF division. These orders are all due for shipment to the customers over the next few months. The increase in inventories within the Stanelco RF division was partially offset by a decrease in inventories within the Bioplastics division.

11. TRADE AND OTHER RECEIVABLES

Trade and other receivables have increased during in the reporting period mainly due to the increases in accrued revenue on the equipment orders under construction within Stanelco RF mentioned above as well as an increase in other debtors within the Bioplastics division.

12. TRADE AND OTHER PAYABLES

The decrease in trade and other payables during the reporting period primarily reflects the timing of trade creditors as at the end of the period.

13. RISKS AND UNCERTAINTIES

The principal risks and uncertainties affecting the business activities of the Group are detailed in the Strategic Report which can be found on pages 6-11 of the Annual Report and Financial Statements for the year ended 31 December 2017 ("the Annual Report"). A copy of the Annual Report and

Financial Statements is available on the Company's website at www.biometechnologiesplc.com

The risks affecting the business remain the same as in the Annual Report. In summary, these risks

include:

   --      changes in the regulatory environments in which the Group operates 
   --      fluctuations in exchange rates 
   --      volatility in raw material prices and supply 
   --      breach of intellectual property rights 
   --      competitors developing more attractive products 
   --      failure to commercialise products 
   --      reliance on a small number of customers for certain products 

-- financial risks including exchange rate risk, liquidity risk, interest rate risk and credit risk.

Further details of how these risks impact the business and how the directors attempt to mitigate

the risks can be found in the Annual Report.

Copies of this interim report will be shortly available on the Company's website at www.biometechnologiesplc.com.

INDEPENDENT REVIEW REPORT FOR BIOME TECHNOLOGIES PLC

Introduction

We have reviewed the condensed set of financial statements in the half-yearly financial report of Biome Technologies Plc (the 'company') for the six months ended 30 June 2018 which comprises the consolidated statement of comprehensive income, consolidated statement of financial position, consolidated statement of changes in equity, consolidated statement of cash flows and the related notes. We have read the other information contained in the half yearly financial report which comprises only the Chairman's Statement and considered whether it contains any apparent misstatements or material inconsistencies with the information in the condensed set of financial statements.

This report is made solely to the company, as a body, in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity'. Our review work has been undertaken so that we might state to the company those matters we are required to state to them in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company as a body, for our review work, for this report, or for the conclusion we have formed.

Directors' responsibilities

The half-yearly financial report is the responsibility of, and has been approved by, the directors. As disclosed in note 2, the annual financial statements of the group are prepared in accordance with International Financial Reporting Standards as adopted by the European Union. The condensed set of financial statements included in this half-yearly financial report has been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union.

Our responsibility

Our responsibility is to express a conclusion to the company on the condensed set of financial statements in the half-yearly financial report based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements (UK and Ireland) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity'. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the half-yearly financial report for the six months ended 30 June 2018 is not prepared, in all material respects, in accordance with International Accounting Standard 34, 'Interim Financial Reporting', as adopted by the European Union.

GRANT THORNTON UK LLP

STATUTORY AUDITOR

CHARTERED ACCOUNTANTS

SOUTHAMPTON

31 August 2018

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IR SDMFWFFASEDA

(END) Dow Jones Newswires

September 03, 2018 02:00 ET (06:00 GMT)

1 Year Biome Technologies Chart

1 Year Biome Technologies Chart

1 Month Biome Technologies Chart

1 Month Biome Technologies Chart
Your Recent History
LSE
BIOM
Biome Tech..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20181218 12:39:19